Life Science Nation Newsletter  | October 5,  2017  |  Issue 234


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Sept. 28  - Oct. 4)
Raises New Fund to Invest Opportunistically in Clinical Stage Life Science Companies
Invests in Advanced Therapeutics
Seeks Oncology, Immunology, Infectious Disease & Diagnostic Assets Worldwide
Invests in Consumer-Facing Health Solutions
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

I am not saying that Biotech Week Boston was the week that wasn't, but for the event's second year, the city of Boston sure didn't feel like it was on fire. Unless of course you went to LSN's RESI Boston event, which was certainly a beehive of activity. It seems like the thesis of Biotech Week Boston is to create a JP Morgan-like annual multi-day event in Boston, the hub of global life sciences. This is a solid goal. The problem is, it's hard to orchestrate and copy an organic phenomenon like San Francisco's JP Morgan week when a handful of the life science stalwarts of Massachusetts partner with an out of town conference provider and they decide who is in and who is out of Biotech Week Boston.

Don't get me wrong, there was plenty of compelling content and the event had a dynamic agenda. Unfortunately, there was more that could have been done; many other compelling players and topics were left on the sidelines. Boston is on the edge of the new drug development models; collaborative virtual pharmas abound. Where were all the incubators and accelerators who are grooming the next generation of game-changing drugs, devices, diagnostics and healthcare IT? Where were all the academic labs and research hospitals that are creating the new tech transfer paradigms and manifesting new business models? What about the other local conference providers like LSN's RESI? LSN brought 300 global early stage investors with $3 billion in validated investor mandates to Boston last week...

By Chris Cummings, Senior Marketing Manager, LSN

With just under six short weeks until the inaugural RESI NYC, LSN is getting ready to assess which health innovators will be awarded a display spot in our RESI Innovation Challenge.

If you would like to participate and get an exhibit hall display spot to market your company to life science investors, the deadline has been extended until Friday, October 13th. (Don't worry, the LSN scientific review team deals in facts, not superstition)。

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company's scientific work...


China: Land of Opportunity for Medical Devices?
By James Huang, Research Analyst, LSN

In my recent discussions with several investors located in China, I noticed a trend occurring in my conversations: many of them are considerably more interested in medical devices rather than therapeutics. As a result, I brought this trend up in conversation with a few of them and received a few illuminating responses:
  • An investor told me that the medical devices market had grown in China by 20% in the past year and they anticipated that this trend would continue over the next few years. The investor therefore hopes to take advantage of this trend. 
  • The Chinese medical device market is currently much smaller than the therapeutics market, and an investor I spoke to said that they therefore believe that there is more potential growth in the medical device market. 
  • China's government is putting money into innovative medical device startups; investors can potentially secure additional non-dilutive funding to go with their investments in medical device companies.

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics